RxDoctor Payments Data

Raheemuddin Nazeer, MD

Rheumatology · Geneva, ILNPI 1043309123

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $70,875 of the $86,879 with a category attached, or 81.6%. Amgen accounts for 92.7% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $51,699 and has fallen 75.7% since, to $12,552 in 2025. Among rheumatology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,879in general payments, 2019–2025

Across 232 payments — averaging $374.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$81K
  • Johnson & Johnson$3K
  • Bristol Myers Squibb$2K
  • AbbVie$1K
  • UCB, Inc.$202
  • Lilly USA, LLC$158
  • plus $405 from 8 others

What the payments were for

  • Consulting fees$9,44211%
  • Speaking & faculty fees$70,87582%
  • Travel & lodging$1,7552%
  • Food & beverage$4,5295%
  • Education$2780%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,879 in reported general payments places this provider in the 95th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,131,509
Medicare patients
375
Services billed
80,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide12$53,255
Colchicine68$4,957
MethotrexateMethotrexate Sodium141$4,612
Hydroxychloroquine Sulfate80$3,597
Leflunomide13$2,252
Azathioprine11$1,828
Prednisone167$1,675
Allopurinol91$1,360
Celecoxib31$779
Alendronate Sodium68$709
Ibandronate Sodium13$483
Methylprednisolone30$242
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen24$226
Gabapentin27$212
Folic Acid15$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$68$53,25512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Geneva

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →